Deep cutaneous fungal infections in solid-organ transplant recipients.

Galezowski, Agnès; Delyon, Julie; Le Cleach, Laurence; Guégan, Sarah; Ducroux, Emilie; Alanio, Alexandre; Lastennet, Diane; Moguelet, Philippe et al. · J Am Acad Dermatol · 2020

retrospective_cohort · Level III

Where this comes from

Abstract

Deep cutaneous fungal infections (DCFIs) are varied in immunosuppressed patients, with few data for such infections in solid-organ transplant recipients (s-OTRs). To determine DCFI diagnostic characteristics and outcome with treatments in s-OTRs. A 20-year retrospective observational study in France was conducted in 8 primary dermatology-dedicated centers for s-OTRs diagnosed with DCFIs. Relevant clinical data on transplants, fungal species, treatments, and outcomes were analyzed. Overall, 46 s-OTRs developed DCFIs (median delay, 13 months after transplant) with predominant phaeohyphomycoses (46%). Distribution of nodular lesions on limbs and granulomatous findings on histopathology were helpful diagnostic clues. Treatments received were systemic antifungal therapies (48%), systemic antifungal therapies combined with surgery (28%), surgery alone (15%), and modulation of immunosuppression (61%), leading to complete response in 63% of s-OTRs. Due to the retrospective observational design of the study. Phaeohyphomycoses are the most common DCFIs in s-OTRs. Multidisciplinary teams are helpful for optimal diagnosis and management.

Medical subject headings